Actively Recruiting
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Led by Incyte Corporation · Updated on 2026-05-04
710
Participants Needed
37
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
CONDITIONS
Official Title
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years old or older
- Have locally advanced or metastatic solid tumor with KRAS G12D mutation
- For certain groups: Disease progressed on prior standard treatment, cannot tolerate or are ineligible for standard treatment, declined known beneficial therapies, or have no standard treatment options
- Meet specific cohort requirements as defined in the protocol
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
You will not qualify if you...
- Prior treatment with any KRAS G12D inhibitor
- Known additional invasive malignancy within 1 year before first dose of study drug
- History of organ transplant including allogeneic stem cell transplantation
- Significant uncontrolled medical condition
- History or presence of an ECG abnormality
- Inadequate organ function
- Other protocol-defined exclusion criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 37 locations
1
Mayo Clinic Hospital
Phoenix, Arizona, United States, 85054
Actively Recruiting
2
Stanford University
Palo Alto, California, United States, 94305
Actively Recruiting
3
UCLA Healthcare Hematology-Oncology
Santa Monica, California, United States, 90404
Actively Recruiting
4
Sarah Cannon Research Institue At Healthone
Denver, Colorado, United States, 80218
Actively Recruiting
5
Mayo Clinic Florida
Jacksonville, Florida, United States, 32224
Withdrawn
6
Florida Cancer Specialists
Sarasota, Florida, United States, 34232
Actively Recruiting
7
Florida Cancer Specialists
Sarasota, Florida, United States, 34232
Withdrawn
8
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
Baltimore, Maryland, United States, 21287
Actively Recruiting
9
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
10
Mayo Clinic
Rochester, Minnesota, United States, 55905
Withdrawn
11
Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601
Actively Recruiting
12
Weill Cornell Medicine
New York, New York, United States, 10021
Actively Recruiting
13
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10022
Actively Recruiting
14
Jefferson University Hospitals
Philadelphia, Pennsylvania, United States, 19107
Actively Recruiting
15
Scri Oncology Partners
Nashville, Tennessee, United States, 37203
Actively Recruiting
16
Md Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
17
Chris Obrien Lifehouse
Camperdown, New South Wales, Australia, 02050
Actively Recruiting
18
St Vincent'S Hospital Sydney
Darlinghurst, New South Wales, Australia, 02010
Actively Recruiting
19
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia, 03000
Actively Recruiting
20
The Alfred Hospital
Melbourne, Victoria, Australia, 03004
Actively Recruiting
21
Linear Clinical Research
Nedlands, Western Australia, Australia, 06009
Actively Recruiting
22
Cliniques Universitaires Ucl Saint-Luc
Brussels, Belgium, 01200
Actively Recruiting
23
Universitair Ziekenhuis Antwerpen (Uza)
Edegem, Belgium, 02650
Actively Recruiting
24
Universitair Ziekenhuis (Uz) Leuven
Leuven, Belgium, 03000
Actively Recruiting
25
The Ottawa Hospital Cancer Center
Ottawa, Ontario, Canada, K1H 8L6
Actively Recruiting
26
Princess Margaret Cancer Center
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
27
Centre Leon Berard
Lyon, France, 69373
Actively Recruiting
28
Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole
Toulouse, France, 31059
Actively Recruiting
29
Institut Gustave Roussy
Villejuif, France, 94805
Actively Recruiting
30
Fondazione Irccs Istituto Nazionale Dei Tumori
Milan, Italy, 20133
Actively Recruiting
31
Irccs Istituto Clinico Humanitas
Rozzano, Italy, 20089
Actively Recruiting
32
Centro Ricerche Cliniche Di Verona
Verona, Italy, 37134
Actively Recruiting
33
National Cancer Center Hospital East
Chiba, Japan, 277-0882
Actively Recruiting
34
The Cancer Institute Hospital of Jfcr
Tokyo, Japan, 135-0063
Actively Recruiting
35
Hospital General Universitario Vall D Hebron
Barcelona, Spain, 08035
Actively Recruiting
36
Fundacion Jimenez Diaz
Madrid, Spain, 28040
Actively Recruiting
37
Hospital Universitario Quironsalud Madrid
Madrid, Spain, 28223
Completed
Research Team
I
Incyte Corporation Call Center (US)
CONTACT
I
Incyte Corporation Call Center (ex-US)
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here